Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3

Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experimental ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 24 September →